Get the Stockscreener App
434.52
0.23%
0.98
After Hours:
433.80
-0.72
-0.17%
Vertex Pharmaceuticals Inc stock is traded at $434.52, with a volume of 1.75M.
It is up +0.23% in the last 24 hours and down -0.72% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$433.54
Open:
$437.07
24h Volume:
1.75M
Relative Volume:
1.36
Market Cap:
$110.28B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
25.76
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
-0.56%
1M Performance:
-0.72%
6M Performance:
+1.82%
1Y Performance:
+0.11%
1-Day Range:
$432.96
$438.84
1-Week Range:
$426.01
$444.32
52-Week Range:
$362.50
$507.92
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharma stock (US92532F1003): Health Canada review for new pain drug puts pipeline in focus - AD HOC NEWS
VRTX: Vertex Pharmaceuticals Seeks Approval for New Pain Treatme - GuruFocus
Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults - PR Newswire Canada
What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock? - Yahoo Finance
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness - Yahoo Finance
Vertex Pharmaceuticals Earnings Call Highlights New Growth Engines - TipRanks
Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout
VRTX Technical Analysis | Trend, Signals & Chart Patterns | VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) - ChartMill
Vertex Pharma stock (US92532F1003): cystic fibrosis leader eyes new growth drivers after latest pipe - AD HOC NEWS
META_TITLE_QUOTE - Yahoo Finance
Vertex Pharma stock (US92532F1003): cystic fibrosis leader eyes gene-editing future - AD HOC NEWS
Vertex Pharmaceuticals’ SWOT analysis: kidney drug stock draws mixed views - Investing.com Australia
VRTX News | VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) - ChartMill
J&J’s Duato makes 358 times his median employee; Vertex CEO makes just 80 times - BioSpace
Vertex Pharma stock (US92532F1003): insider selling puts focus on biotech heavyweight - AD HOC NEWS
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Inc (VRTX) Stock Price, Trades & News - GuruFocus
Vertex Pharmaceuticals Insider Sold Shares Worth $613,971, According to a Recent SEC Filing - Moomoo
VRTX: CF and pipeline innovation drive growth, with JOURNAVX and Povi poised for major impact - TradingView
Vertex (VRTX) CSO Mark Bunnage sells 33 shares in pre-set 10b5-1 trade - Stock Titan
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharma stock (US92532F1003): cystic fibrosis leader after solid quarterly results - AD HOC NEWS
North Dakota State Investment Board Buys Shares of 8,821 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Canada Post Corp Registered Pension Plan Has $2.94 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock (US92532F1003): focus on cystic fibrosis and expanding pipeline - AD HOC NEWS
Vertex Pharma stock (US92532F1003): institutional flows and pipeline keep focus on biotech heavyweig - AD HOC NEWS
Vertex Pharmaceuticals stock (US92532F1003): gene-editing hopes meet kidney data buzz - AD HOC NEWS
Leuthold Group LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
STF Management LP Lowers Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (VX1.DE) Stock Price, News, Quote & History - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX.VI) Stock Price, News, Quote & History - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by DNB Asset Management AS - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Allworth Financial LP Has $6.36 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex Pharma stock (US92532F1003): Q1 numbers, ESOP shelf and gene-editing momentum draw investor f - AD HOC NEWS
Vertex Pharmaceuticals (NASDAQ: VRTX) insider files Form 144 to sell vested shares - Stock Titan
Mark Bunnage sells shares at VRTX (NASDAQ: VRTX) in Form 144 filing - Stock Titan
FY2027 Earnings Forecast for VRTX Issued By Erste Group Bank - MarketBeat
Daiwa Securities Adjusts PT on Vertex Pharmaceuticals to $555 From $561, Maintains Buy Rating - marketscreener.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Atria Investments Inc - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Carmen Bozic Sells 6,988 Shares - MarketBeat
Vertex (VRTX) CMO Carmen Bozic sells 6,988 shares in planned 10b5-1 trade - Stock Titan
Capital World Investors (NASDAQ: VRTX) reports 10.1% stake in Vertex - Stock Titan
Vertex Pharmaceuticals stock (US92532F1003): Shareholder approval fuels biotech momentum - AD HOC NEWS
Capital Research discloses 21.1M-share stake in Vertex (NASDAQ: VRTX) - Stock Titan
Vertex Pharma stock (US92532F1003): Shares up 1.06% to $453 amid biotech strength - AD HOC NEWS
Vertex Pharmaceuticals posts mixed Q1; investors focus on non-CF pipeline for growth - MSN
Pacer Advisors Inc. Buys 9,641 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Sells 10,154 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Baader Bank Aktiengesellschaft Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):